In the BLOOM study, osimertinib 160 mg orally once daily resulted in a leptomeningeal lesions ORR of 62% and a median PFS of 8.6 months in treated EGFR mutated NSCLC with leptomeningeal metastases [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.